Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)

Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Mersana Therapeutics (MRSN – Research Report) today and set a price target of $9.00. The company’s shares opened today at $2.67.

Goonewardene covers the Healthcare sector, focusing on stocks such as Genmab, Iovance Biotherapeutics, and Mersana Therapeutics. According to TipRanks, Goonewardene has an average return of -3.6% and a 32.31% success rate on recommended stocks.

In addition to Truist Financial, Mersana Therapeutics also received a Buy from Leerink Partners’s Jonathan Chang in a report issued on May 9. However, on the same day, Robert W. Baird maintained a Hold rating on Mersana Therapeutics (NASDAQ: MRSN).

The company has a one-year high of $9.62 and a one-year low of $0.80. Currently, Mersana Therapeutics has an average volume of 2.17M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mersana Therapeutics (MRSN) Company Description:

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.